Cardiovascular Effects of Glucagon-Like Peptide 1

E-ISSN： 1875-5607|11|1|97-105

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.11, Iss.1, 2011-01, pp. : 97-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

By Saraceni Christine Broderick Tom L.

Drugs in R&D, Vol. 8, Iss. 3, 2007-01 ,pp. : 145-153

Adis International

Access to resources Recommend Favorite

Renal effects of glucagon-like peptide in rats

By Moreno C. Mistry M. Roman R.J.

European Journal of Pharmacology, Vol. 434, Iss. 3, 2002-01 ,pp. : 163-167

Elsevier

Access to resources Recommend Favorite

The glucagon-like peptide-1 analogue liraglutide effectively improves cardiovascular (CV) parameters in patients with type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1560, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2

By Brubaker Patricia L Anini Younes

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 11, 2003-11 ,pp. : 1005-1012

NRC Research Press

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite